FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:634-635 August 11, 2005 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Dr. Licata reports in his letter to the editor (May 5 issue)¹ that the increase in serum calcium levels after treatment of osteoporosis with the parathyroid hormone derivative teriparatide correlates "inversely with 25-hydroxyvitamin D." Therefore, vitamin D supplementation to increase the level of 25-hydroxyvitamin D might be desirable. Indeed, Dr. Licata's own data show that patients with higher levels of 25-hydroxyvitamin D have a reduced risk of hypercalcemia.

Given this finding, we are very surprised that Dr. Licata advises caution in the use of vitamin D supplementation. Dr. Licata's letter focuses on the increase in levels of . . . [Full Text of this Article]

Related Letters:

Osteoporosis, Teriparatide, and Dosing of Calcium and Vitamin D
Licata A. A.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:1930-1931, May 5, 2005. Correspondence

This article has been cited by other articles:

• Kimball, S. M, Ursell, M. R, O'Connor, P., Vieth, R. (2007). Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 86: 645-651 [Abstract] [Full Text]  
• Miller, P. D., Bilezikian, J. P., Diaz-Curiel, M., Chen, P., Marin, F., Krege, J. H., Wong, M., Marcus, R. (2007). Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide. J. Clin. Endocrinol. Metab. 92: 3535-3541 [Abstract] [Full Text]